arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

IMPACT BIOMEDICAL INC.

IBO

$6.62 ▲ +6.08 (+1123.66%) at close

4 Visible periods

23 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

IMPACT BIOMEDICAL INC. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $208.9M

Dividend Yield —

Revenue Growth —

Op. Margin —

ROIC -27.9% ↗

FCF / Share $-0.06 ↗

Trailing P/E —

Price / Book 54.9x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Sep 23, 2026.

4-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$32.00K

↓ -36.0% —

Net Income Profit after all expenses

$-11.84M

↑ +52.1% —

FCF / Share Free cash flow per share

$-0.06

↑ +77.4% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓

Financial Health ↑

Cash Quality ↓

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗
EPS Growth YoY (%)	83.5% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	-3185.7% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	30.0% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	—
Net Income Growth YoY (%)	52.1% Excellent ↑ Excellent Improving Year-over-year change in net income	-469.8% Weak Weak Year-over-year change in net income	40.2% Excellent Excellent Year-over-year change in net income	—
FCF Growth YoY (%)	77.4% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	-460.7% Weak Weak Year-over-year change in free cash flow	-48.8% Weak Weak Year-over-year change in free cash flow	—
Revenue CAGR 3Y (%)	-13.8% Weak Weak Compound annual revenue growth over 3 years	—	—	—

💰 Are margins durable? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗
Effective Tax Rate (%) (%)	17.9% Good ↑ Good Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.1% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—	7.9% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%
FCF / Net Income (x)	0.16x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.12x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.66x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	0.31x Weak Weak Free cash flow relative to reported net income Optimal: > 1x

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗
Return on Invested Capital (%)	-27.9% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-676.0% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-12.6% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	-10.6% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%
Return on Capital (%) (%)	-24.6% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-141.7% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-9.0% Weak Weak Operating profit relative to total assets Optimal: > 10%	-7.3% Weak Weak Operating profit relative to total assets Optimal: > 10%
Return on Common Equity (%) (%)	-93.9% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-726%)	—	-17.2% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-215%)	-24.5% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-264%)

⚖️ Is the balance sheet risky? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗
Interest Coverage (x)	-5.40x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-27.00x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-9.07x Weak Weak Operating income divided by interest expense Optimal: > 5x	-7.37x Weak Weak Operating income divided by interest expense Optimal: > 5x
Net Debt (USD)	$-3.00K	$-2.00M	$-1.00K	$-2.00K

📊 What does each share earn? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗
Revenue per Share (USD)	$0.00	—	—	$0.00
Basic EPS, GAAP (USD)	$-0.38	$-2.30	$-0.07	$-0.10
Free Cash Flow per Share (USD)	$-0.06	$-0.27	$-0.05	$-0.03
Book Value per Share (USD)	$0.12	$0.37	$2.52	$0.42
Tangible Book Value per Share (USD)	$0.12	$0.37	$-2.12	$0.06
Basic Weighted Avg Shares (shares)	31.55M	10.76M	60.25M	70.50M

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗
Working Capital (USD)	$-751.00K	$-7.34M	$-12.80M	$-10.47M
Total Equity (USD)	$12.61M	$4.26M	$25.22M	$29.56M

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗
Sales/Revenue/Turnover (USD)	$32.00K	—	—	$50.00K
Depreciation Expense (USD)	$1.15M	$1.12M	$1.12M	$1.11M
Net Income, GAAP (USD)	$-11.84M	$-24.71M	$-4.34M	$-7.25M
Operating Cash Flow (USD)	$-1.89M	$-2.85M	$-2.85M	$-2.24M

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 4 years · 17 quarters

IMPACT BIOMEDICAL INC.

Analytical Summary

4-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare IBO with peers